"We are open, we have the capacity" Bancel said about supplying its mRNA-based shots to the country, declining to say whether Moderna had s...

Moderna has been studying the so-called bivalent vaccine, which targets both Omicron and the original coronavirus strain to determine if it...

India also assured the world that it was determined to become the global vaccine capital and it is now in a position to ensure adequate sup...

Now that kids under 6 are the only strata of population that still does not have a vaccine, this move by Moderna might just be the final pi...

A vaccine focused directly on the Omicron variant would also guard against breakthrough infections of a strain that has proven highly conta...

The Sensex slumped 1,100 points from the day's high of 58,183.77 before closing at 57,064.87, down 195.71 points or 0.3 per cent from the p...

In initial trade, London's benchmark FTSE 100 index reversed 0.9 percent to 7,047.14 points.

The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they...

"If you look at the industry-wide expansion of production capacities over the past six months, enough doses should be available by the midd...

"We are encouraged that the Moderna Covid-19 vaccine was highly effective at preventing Covid-19 and SARS-CoV-2 infection in adolescents," ...

Speaking at a virtual event on vaccine manufacturing, Stephane Bancel said that additional technology transfers might dent their ability to...

A company press release did not indicate why efficacy has fallen, but one reason might be the emergence of new variants of concern which ar...

Pfizer, which makes a similar COVID-19 vaccine, has previously reported that its shot also appears effective against the strain from Britai...

On Monday, an EU official involved in the talks said the European Commission wanted to reach a deal with Moderna for the supply of millions...

While the company did not give a clear timeline on the release of data from these trials on Thursday, it has said that early data is expect...

The Cambridge, Massachusetts-based company said the vaccine candidate, mRNA-1273, appeared to produce an immune response in eight people wh...

The study was primarily designed to look at the safety of the shot and showed no major warning signs in a small phase 1 trial, the company ...